Brief: Oncolytics Biotech Q1 loss 3 cents/shr
May 6 (Reuters) -
* Oncolytics biotech inc. Announces 2016 first quarter
results
* Oncolytics biotech inc qtrly loss per common share $0.03
Source text for Eikon: ID:nPn1RctZ0a
Further company coverage: ONC.TO
(Bengaluru Newsroom +1-646-223-8780)
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer